Intralinks Holdings, Inc. IL
Set alert
13.01 +13.01 —
At close · Jun 28
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- —
- High
- —
Financials — quick view
IL Revenue — quarterly 75.41M
IL Net income — quarterly -1.23M
IL EPS — quarterly -0.02
News
- AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AI Use Permeates Dealmaking Despite Operational Concerns: SS&C Intralinks Report
- SS&C Intralinks Predicts M&A Deal Flow Resilience in Q1 2025
- SS&C Intralinks Predicts M&A Deal Flow Rising Globally in Q4 2024
- SS&C Intralinks Releases 2025 Limited Partner Survey Results
- Intralinks Announces Date of Earnings Release and Conference Call for its Third Quarter 2016 Financial Results
- Intralinks Announces Date of Earnings Release and Conference Call for its Second Quarter 2016 Financial Results
Your note
Sign in to keep a note on IL — it syncs with the Stock Master app.